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Abstract: The GJB2 gene is located on chromosome 13q12 and it encodes the connexin 26, a transmembrane protein 
involved in cell-cell attachment of almost all tissues. GJB2 mutations cause autosomal recessive (DFNB1) and sometimes 
dominant (DFNA3) non-syndromic sensorineural hearing loss. Moreover, it has been demonstrated that connexins are 
involved in regulation of growth and differentiation of epidermis and, in fact, GJB2 mutations have also been identified in 
syndromic disorders with hearing loss associated with various skin disease phenotypes. GJB2 mutations associated with 
skin disease are, in general, transmitted with a dominant inheritance pattern. Nonsyndromic deafness is caused prevalently 
by a loss-of-function, while literature evidences suggest for syndromic deafness a mechanism based on gain-of-function. 
The spectrum of skin manifestations associated with some mutations seems to have a very high phenotypic variability. 
Why some mutations can lead to widely varying cutaneous manifestations is poorly understood and in particular, the 
reason why the skin disease-deafness phenotypes differ from each other thus remains unclear. This review provides an 
overview of recent findings concerning pathogenesis of syndromic deafness imputable to GJB2 mutations with an 
emphasis on relevant clinical genotype-phenotype correlations. After describing connexin 26 fundamental characteristics, 
the most relevant and recent information about its known mutations involved in the syndromic forms causing hearing loss 
and skin problems are summarized. The possible effects of the mutations on channel expression and function are 
discussed. 
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1. INTRODUCTION 
Sensorineural hearing loss is a very heterogeneous disorder 
showing different pattern of inheritance and involving a 
multitude of different genes. Several forms of hearing loss 
have been imputated to connexins mutations and prevalently 
to connexin 26 (Cx26) codified by the GJB2 gene (gap 
junction protein, beta 2). 
  Up to now 21 connexins have been established in humans 
[1], each coding for a transmembrane protein with the same 
protein topology. Connexins oligomerize with five other 
connexin molecules to form a connexon (Fig. 1A-B). 
Connexins are synthesized in the endoplasmic reticulum 
(ER) and oligomerize in the ER/Golgi or trans-Golgi 
network to form connexons [2]. Connexons are subsequently 
transported to the plasma membrane by vesicular carriers 
travelling along microtubules. Connexons in adjoining cells 
fuse through disulfide bonding to form gap junctions (GJ) 
(Fig. 1C) [3]. The combination of several connexins lead to 
diverse connexons and GJ channels with different properties 
according to the needs of each cell type [4]. Connexins are, 
in fact, expressed throughout the body and most cells express 
more than one type of connexin, thus connexons may either 
stem from a single species (homomeric) or different Cx 
(heteromeric) and depending on the compatibility of   
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interacting connexons. This diversity is amplified at the level 
of intercellular channels, which can be formed by similar 
(homotypic channels) or different homomeric connexons 
(heterotypic channels), or two heteromeric Cx (heteromeric 
channels)  [5]. Newly formed connexons tend to move 
laterally towards existing GJ channels, thus forming large 
gap junction plaques. Depending on the cell type and the 
connexin expressed, connexons can function as 
hemichannels, forming a direct transmembrane commun-
ication pathway, enabling the permeation of ions, but also of 
small metabolites such as ATP, cAMP, IP3 and glutamate. 
Connexons can thus act as secretory pathways and mediate a 
paracrine signalling. However, they generally must be tightly 
regulated to avoid loss of metabolites and of ionic gradients 
across the membrane. In fact, aberrant opening of 
hemichannels usually leads to cell death, and most 
connexons remain in closed conformation in the 
physiological state. GJ channels instead, will enable a direct 
communication pathway between the cytoplasms of adjacent 
cells mediating a direct exchange of ions but also of small 
molecules up to 1 kDa between the cytoplasms of adjacent 
cells [6]. 
  According to structural similarity, connexins are divided 
into two major groups: connexins alpha and beta [7, 1]. GJ 
appeared to be highly selective as many connexins are 
restricted in their capability to form functional channels with 
other members of this family especially when it concerns the 
connexins from alfa and beta groups [7]. 476    Current Genomics, 2011, Vol. 12, No. 7  Iossa et al. 
  Several connexins are involved in human pathologies [6]. 
It is actually reported that connexins 26, 29, 30, 30.3, 31, 32, 
and 43 codified respectively by GJB2, GJE1, GJB6, GJB4, 
GJB3, GJB1and GJA1 genes are involved in human diseases 
affecting cochlea and some of them (Cx26, Cx30, Cx30.3, 
Cx31 and Cx43) have been involved too in syndromic form 
of hearing loss affecting coclea in combination with 
epidermis [8-10]. 
  Mutations in the gene GJB2 (Cx26) are responsible for 
the major portion of genetic forms of sensorineural hearing 
loss (SNHL) (http://hereditaryhearingloss.org/). GJB2 gene 
(OMIM 121011) mutations account for up to 50% of 
prelingual recessive non-syndromic deafness, in Caucasian 
and European populations [11-13] and it is also involved in 
vestibular dysfunction [14]. Few specific mutations in the 
GJB2 gene also underlie autosomal non-syndromic deafness 
DFNA3  [15]. A digenic model of inheritance has been 
proposed in some cases; mutations affecting the GJB6 gene, 
which encodes connexin-30 (OMIM 604418), have been 
described in association with GJB2 mutations thereby 
determining a double heterozygous genotype [16, 17]. 
2. GJB2 (CX26) STRUCTURE 
 GJB2 gene is located on chromosome 13q12. The 
structure of the GJB2 gene, as well the structure of other gap 
junction genes, is simple (Fig. 2). An untranslated exon 1 is 
separated by an intron of 3179 bp length from exon 2, 
containing the uninterrupted coding region and the 3'-
untranslated region (3'-UTR) (Fig. 2). GJB2 gene encodes 
Cx26 protein, that consists of four alfa-helical 
transmembrane domains (TM1–TM4), two extracellular 
loops (EC1 and EC2), a cytoplasmic aminoterminal domain 
(IC1), a cytoplasmic loop (IC2) between TM2 and TM3, and 
a carboxy-terminal (IC3) domain [18] (Fig. 3). The two latter 
domains are characteristic of each connexin, while the 
membrane spanning and the extra cellular domains are 
highly conserved among the entire protein family [7, 19]. 
Under physiological conditions the extra cellular portions of 
connexons interact with connexons of opposing cells in the 
intercellular space to complete functional active channels. 
The cytoplasmic loop and the N-terminus of the protein 
located at the cytoplasmic side of the channel pore are 
involved in voltage and ion gating and are thought to be 
essential for the regulation of channel selectivity [20].  
3. CONNEXIN EXPRESSION IN COCHLEA AND 
EPIDERMIS 
  Several connexin are expressed in the cochlea, but the 
most abundant expression was found for Cx26 and Cx30 
proteins which co-localize and can form heteromeric 
channels. They are expressed in nonsensory epithelial cells 
among which hair cells are dispersed and connective tissue 
cells at more distal locations to the hair cells. Despite several 
studies their function in inner ear is poorly understood. In 
these cells it has been supposed that gap junctions are 
important for maintaining the endocochlear potential being 
involved in recycling endolymphatic K+ ions from the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic structure of connexins, hemichannels (connexons) and gap junctions. A) Connexins are integral membrane proteins 
involved in many biological functions. B) Connexons are constituted by six connexins wich are joined to form in their center an aqueous 
pore that extends connecting the cytoplasms of the two cells. C) The gap junction units are made up of twelve copies of the connexin 
molecules arranged into two hexamers (connexons), one associated with each cellular membrane and providing a pathway for the transfer of 
ions and other small molecules between the cells. GJB2 in Syndromic Hearing Loss  Current Genomics, 2011, Vol. 12, No. 7    477 
sensory hair cells back to the endolymph [21]. Data suggest 
that the role of gap junction communication in the cochlea 
may not be limited to K+ recycling and it has been shown 
alteration in biochemical coupling, thus proposing that 
metabolite transfer between cells is the determinant role of 
gap junction for K+ homeostasis of the inner ear [22, 23]. 
  In the epidermis several connexins are expressed in a 
partially overlapping pattern. Noteworthy, non-differentiated 
basal keratinocytes express alfa connexins, while beta 
connexins prevail in differentiated keratinocytes. Cxs known 
to be expressed in human epidermis include Cx26, Cx30, 
Cx30.3, Cx31, Cx31.1, Cx37 and Cx43 [6, 24, 25]. In human 
skin, only the expression patterns of Cx43 and Cx26 have 
been studied in detail to date. Cx43 is expressed in 
interfollicular epidermis, particularly in the spinous and 
granular cell layers, in sebaceous glands and in hair follicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). GJB2 molecular structure and localization. GJB2 gene is localized in 13q11 chromosome and it is constituted by two exons: only 
the exon 2 is a coding one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Connexin26 molecular structure and known syndromic mutations. Connexins are proteins constituted by four transmembrane 
domain: TM1-TM4, two extracellular loops: EC1 and EC2, and four intracellular domains: IC1 (NH2-terminal), IC2, and IC3 (COOH-
terminal). Known mutations in Cx26 associated with syndromic forms of hearing loss are reported.  
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Cx26 is present in hair follicles, and in eccrine sweat glands 
and ducts, but it is much less abundant in normal epidermis, 
being seen mainly in the skin of palms and soles [26, 27].  
  Cx26 plays an important role in the regulation of both 
keratinocyte proliferation and differentiation even though it 
is barely expressed in normal adult epidermis in humans and 
in rodents [7]. Cx26 expression is induced during wound 
healing, psoriasis, and skin hyperplasia stimulated by tumor 
promoters. In hyperplastic proliferating epidermis, Cx26 is 
co-expressed with Cx43 typical for basal and suprabasal 
keratinocytes. As Cx26 and Cx43 can not form permeable 
gap junctions, their co-expression may alter the gap 
junctional communication between keratinocytes and induce 
proliferation [28, 29]. 
4. SYNDROMIC FORMS IMPUTABLE TO GJB2 
MUTATIONS 
 GJB2 mutations, as well as other connexins, have been 
reported as causative for several syndromic forms of hearing 
loss associated to skin problems. The GJB2 mutations are 
reported in Table 1.  
  All these syndromic forms have an autosomal dominant 
pattern of transmission. As well as for the hearing loss, the 
clinical phenotypes associated have a large variability, the 
type and the severity of the skin disorders caused by Cx26 
mutations are very heterogeneous and sometimes are present 
only features of incomplete syndrome (Table 2). The 
phenotypic variability is observed even among carriers of the 
same connexin mutation [30-33] (Table 2). 
  Below is reported a brief description for each syndrome:  
A. Keratitis-Ichthyosis-Deafness (KID) Syndrome 
  KID syndrome is a rare congenital ectodermal disorder, 
characterized by the presence of skin lesions, mild to 
profound sensorineural hearing loss, and vascularizing 
keratitis that can result in progressive decline of visual acuity 
and may eventually lead to blindness. The skin lesions, 
described as erythrokeratoderma are not restricted to 
particular regions of the body and show marked ichthyosis 
with increased susceptibility to mucocutaneous infection 
sometimes fatal in the neonatal period [34]. Additional 
phenomena are dystrophic nails, dental abnormalities and 
scarring alopecia. Sometimes, it is reported increased 
carcinogenic potential [35-37]. 
B. Hystrix-Like Icthyosis Deafness Syndrome (HID) 
  HID deafness syndrome is similar to KID syndrome and 
displays all of the common features of KID. Symptoms are 
bilateral hearing loss and spiky hyperkeratotic masses which 
cover the whole body though the palms and soles are less 
badly affected. It can be differentiated from KID syndrome 
which also has symptoms of deafness and ichthyosis by the 
different distribution of hyperkeratosis. Actually, it is 
supported the idea that these two syndromes might represent 
a single form of syndromic deafness with a heterogeneous 
phenotype. Combined with the similarities between 
Vohwinkel syndrome (VS), Bart–Pumphrey syndrome (BPS) 
and palmoplantar keratoderma (PPK), the emerging view is 
that there are two broad types of skin disorder associated 
with syndromic deafness: the VS–BPS–PPK group and the 
KID–HID group [38].  
C. Palmoplantar Keratoderma with Deafness Syndrome  
 Palmoplantar keratoderma is another syndromic 
complication of deafness (mild to profound SNHL). 
Hereditary palmoplantar keratodermas (PPK) comprise a 
clinically and genetically heterogeneous group of 
genodermatoses, which share impaired epidermal 
differentiation resulting in prominent palmoplantar 
hyperkeratosis. Classically, keratodermas have been 
separated according to their clinical appearance into diffuse, 
focal, and as a feature of ectodermal dysplasias and many 
other syndromes [39]. 
D. Vohwinkel Syndrome 
  Vohwinkel sindrome is another skin disease associated 
with SNHL. The skin problem is characterized by disturbed 
epidermal differentiation manifested by hyperkeratosis 
especially on the palms and soles (keratoderma), which, in 
the case of VS, often becomes mutilating with starfish-
shaped proximal extensions and hyperkeratotic bands around 
the fingers, so-called pseudoainhum, sometimes leading to 
auto-amputation [40,41].  
E. Bart–Pumphrey Syndrome  
  Bart–Pumphrey syndrome, is a rare autosomal dominant 
disorder characterized by congenital SNHL, palmoplantar 
hyperkeratosis, knuckle pads, and leukonychia (nail 
thickening and crumbling) [42-44].  
Table 1.  Syndromic Forms Imputable to GJB2 Mutations 
Syndrome Mutations  OMIM  code 
Keratitis-ichthyosis- deafness (KID)  G11E, G12R, N14K, N14Y, S17F, I30N, A40V, G45E, D50N, D50Y, A88V  148210 
Ichthyosis, hystrix-like-deafness (HID)  D50N, D50Y  602540 
Palmoplantar keratoderma- deafness (PPK)  Delta E42, N54H, G59A, G59R, H73R, R75Q, R75W, G130V, S183F  148350 
Vohwinkel   G59S, Y65H, D66H, G130V  124500 
Burt-Pumphrey N54K,  G59S  149200 
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Table 2.  GJB2 Mutations Involved in SHL: Principal Phenotypic Characteristics and Proteic Domains Affected  
Mutations Syndrome  Phenotypes 
Ear Skin 
Protein 
domain 
References 
G11E  KID  Profound SNHL  Hyperkeratosis, ocular problems, alopecia  IC1  [20] 
G12R KID  Mild  SNHL  Limited hyperkeratosis. Mild ocular 
problems 
IC1  [8,73] 
N14K KID/EKV  Severe  SNHL  EKV-like: hypotrichosis, nail dystrophy, 
mucositis and skin lesions 
IC1  [74] 
N14Y  KID  Profound SNHL  Hyperkeratosis palms and 
soles, impetiginous plaques on 
neck, axilla, perianal areas and occipital 
area, ocular problems 
IC1  [75] 
S17F  KID  SNHL  Visual impairment, in one case 
lethal carcinoma of the tongue; sometimes 
trichothiodystrophy-like hair abnormalities 
IC1  [8,76,77] 
I30N  KID  Profound SNHL  Skin necrosis  TM1  [78] 
A40V KID  Profound  SNHL  Mild palmoplantar keratoderma, follicular 
hyperkeratosis, occlusion triad 
TM1/EC1 
boundary 
[79] 
Delta E42  PPK  Profound SNHL  Diffuse PPK  TM1/EC1 
boundary 
[9] 
G45E KID  Profound SNHL; inner ear 
abnormality: dysplasia of the cochlear 
and saccular neuroepithelium. 
Severe skin lesion infections and 
septicaemia:fatal form. 
In japanese population is not fatal: it is 
responsible only for a recessive non 
syndromic form of SNHL 
TM1/EC1 
boundary 
[34,56,80,81] 
D50N KID/HID Profound SNHL and sometimes 
conductive HL 
Photophobia, keratitis, and 
erythrokeratoderma; sometimes in 
association with follicular occlusion triad 
EC1  [76,82-84] 
D50Y KID/HID  Profound  SNHL  Photophobia, keratitis, and 
erythrokeratoderma 
EC1  [85] 
N54H  PPK  Profound SNHL  PPK and knuckle pads  EC1  [86] 
N54K BPS  Profound  SNHL  PPK, prominent knuckle pads, and 
leukonychia 
EC1  [42] 
G59A PPK  H.F.  SNHL  PPK  EC1  [30] 
G59R  PPK  SNHL: Mild at L.F.-severe at H.F.  Striate PPK  EC1  [87] 
G59S  Atypical BPS 
or Atypical 
Vohwinkel 
Severe SNHL 
Profound SNHL 
Knuckle pads, PPK/ ichthyosis, massive 
mutilating keratoderma, proneness to skin 
cancer 
EC1  [88,89] 
Y65H Vohwinkel  Moderate  SNHL  Mutilating  PPK  EC1  [90] 
D66H  Vohwinkel  Moderate to severe SNHL  Mutilating PPK  EC1  [91] 
H73R  PPK  Severe progressive SNHL  Focal PPK similar to Vohwinkel with large 
intrafamilial variability 
EC1  [49] 
R75W  PPK  Severe to profound SNHL  Variable: generally PPK and some times 
knuckle pads 
EC1/TM2 
boundary 
[92,93] 
R75Q  PPK  Severe to profound SNHL  PPK (not ever present)  EC1/TM2 
boundary 
[33,55] 
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(Table 2). Contd….. 
Mutations Syndrome  Phenotypes 
Ear Skin 
Protein 
domain 
References 
A88V  KID  Severe to profound SNHL  Severe skin lesion infections and 
septicaemia:fatal form 
TM2  [94] 
G130V PPK  or 
Vohwinkel 
Severe SNHL Profound HL  Mild PPK 
PPK and skin constrictions 
IC2  [31,57] 
F142L  Unususal 
mucocutaneous- 
deafness 
Severe to profound SNHL  Psoriasiform mucocutaneous 
involvement, inflammation of mucous 
membranes 
TM3  [95] 
S183F  PPK  H. F. SNHL  Focal PPK and some times knuckle pads  EC2  [49] 
EKV: erythrokeratodermia variabilis; H. F. : high frequency; L. F. : low frequency. 
5. FUNCTIONAL STUDIES 
  The properties of several specific mutations in connexins 
involved in ear-skin problems have been investigated in 
more detail in several studies principally at a cellular level, 
using either transfected mammalian cells or Xenopus oocyte. 
These studies give first of all several information about 
dominant inhibition on wild type connexins [9,45-50]. The 
more recent and convincing study on dominant inhibition has 
been realized by Zhang [51] transfecting HeLa cells stably 
expressing wild type with three Cx26 mutants associated 
with hearing loss and palmoplantar keratoderma (p.G59A, 
p.R75Q, and p.R75W). All mutants co-localized and 
coimmunoprecipitated with wild type Cx26, indicating that 
they interact physically, moreover, these mutants inhibited 
the transfer of calcein in cells stably expressing Cx26, 
demonstrating that they each have dominant negative effects 
on wild type Cx26. Functional studies gives also several 
information on connexin trafficking and presence and 
properties of hemichannels and gap junctions (Tables 3 and 
4).  
6. DISCUSSION 
  It has been demonstrated that connexins have a great 
importance in many human biological processes. Connexins 
are expressed in several tissues, but in many cases their 
effects are restricted to particular organs and mutations in a 
connexin can affect one organ expressing this protein, but 
these mutations do not affect other tissues expressing the 
same protein. The precise mechanism for this selectivity for 
organ involvement is actually unknown and it can only 
partially be explained by redundancy in connexin expression 
or by a specific regulation at the transcriptional level as an 
alternative splicing [52]. Several data have highlighted, in 
particular, the importance of some connexins in the cochlea 
and in the skin. The essential role of connexins in the human 
cochlea and skin was, in fact, evident from association 
between mutational changes, deafness [12, 53] and/or skin 
problems. A chief role in deafness and skin pathologies is 
carried out by the GJB2 gene. In fact, mutations in the GJB2 
gene coding for Cx26 can cause a variety of deafness and 
hereditary hyperproliferative skin disorders in humans. The 
majority of these mutations, causative of a non–syndromic 
form of hearing loss, are inherited in an autosomal recessive 
manner, but several mutations have been also associated 
with dominantly inherited forms both non-syndromic and 
syndromic.  
  In syndromes associated to GJB2 mutations (Table 1) are 
affected specifically the ear and the epidermis. The lack of 
associated skin disorders in cases of nonsyndromic SNHL 
shows that the function and development of the epidermis is 
not affected by the simple loss of Cx26 function as in the 
case of homozygous c.35delG patients. In this case a likely 
explanation is that one or more of the several other 
connexins expressed in epidermis can compensate for 
homozygous loss of Cx26. However, while other connexins 
may compensate for loss of Cx26 from epidermis (but not in 
the inner ear), they cannot overcome the effects of the 
dominant mutations. Thus, the Cx26 mutations that can 
cause syndromic deafness associated with skin disease must 
show some type of alteration of function, but the 
mechanisms whereby Cx26 mutation leads to pathological 
changes remain to be elucidated.  
  Phenotype associated to identified mutations is largely 
variable, broad clinical patterns emerge for the wide range of 
clinical manifestations and rates of progression (Table 2). 
Sometimes the clinical pattern is very serious, even fatal 
(p.G45E and p.A88V mutations) (Table 2). A high 
phenotypic variability has been observed in close aminoacids 
(p.G11E, p.G12R), sometimes giving also origin to different 
syndromes (p.A40V: KID and Delta E42: PPK) (Table 2). It 
has been observed a variable expressivity also for different 
mutations in the same amino acid: p.N14K- p.N14Y, 
p.G59A- p.G59R- p.G59S, p.R75W- p.R75Q. [32, 54]. The 
amino acid N14 is near two of the residues mutated in 
Keratitis-like ichthyosis deafness (KID) syndrome (p.G12R 
and p.S17F), yet the phenotype associated with p.N14K 
strongly differs from the KID phenotype, having a 
phenotype more similar to Clouston syndrome (caused by 
mutations in GJB6). However, a different mutation at the 
same location, p.N14Y, was reported to cause a disorder 
similar to KID. p.G59A and p.G59R have been indicated as 
causative of PPK, while p.G59S has been indicated as 
causative in an atypical form of BPS as well as in an atypical 
form of Vohwinkel (Table 2). One hypothesis to explain the 
phenotypic differences in these cases may be that distinct 
substitutions cause different conformational changes to the 
protein, each with unique consequences for its behaviour. 
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Table 3.  Altered Properties Identified by Functional Assays for Cx26 KID Mutations 
Mutation  Trafficking  Hemichannels  Functional GJ channels  Observations  References 
G11E Altered  Aberrant  opening  Absent  Increase of calcium uptake, 
increase of cellular death by 
necrosis 
[20] 
G12R  OK  Increased function  Absent  Increased cell death  [59] 
N14K OK  Increased  function Present, but with loss of 
voltage gating 
Increased cell death  [59] 
N14Y -  -  Absent  Reduced GJ intercellular 
communication 
[75] 
S17F  OK  Complete loss of functions  Absent  No increased cellular lethality  [59] 
A40V  OK  Leaky hemichannels  Present  Increased cell death  [79,96,97] 
G45E  OK  Excessive entry of Ca
2+  Present  Increased cell death  [79,96,97] 
D50N -  Increased  function  -  Increase of calcium uptake, 
increase of cellular death by 
necrosis and apoptosis 
[20,59] 
 
Table 4.  Altered Properties Identified by Functional Assays for Cx26 PPK and Vohwinkel Mutations 
Mutation Trafficking  Hemichannels Functional GJ 
channels 
Observations References 
Delta E42  OK  -  Absent  -  [9,98] 
G59A OK  Heteromeric: inhibition of 
calcein transfer  
Present -  [52,99] 
Y65H Altered  -  Absent  -  [90] 
D66H Altered  -  Absent  -  [45,49,100] 
H73R Altered  -  -  -  [49] 
R75W OK  Heteromeric: inhibition of 
calcein transfer 
Present -  [51,99] 
R75Q OK  Heteromeric: inhibition of 
calcein transfer 
Present -  [51,99] 
 
palmoplantar keratoderma phenotype does not consistently 
occur with the hearing loss giving origin to a non-syndromic 
form of hearing loss. This high phenotypic variability 
observed, even among carriers of the same connexin 
mutation  [32, 55] (Table 2) it has been observed also for 
p.G45E and p.G130V mutations. The p.G45E mutation, 
reported as causative of a syndromic fatal form of KID 
(Table  2), is however, the third most common GJB2 
mutation (16% of disease alleles) in Japanese patients with 
autosomal recessive non-syndromic HL [56]. This finding 
suggests different modes of action of the same GJB2 
mutation depending on the genetic background. Instead, 
p.G130V is reported as causative of two different syndromic 
forms: PPK and Vohwinkel (Tables 1 and 2) [31, 57].  
  To explain the differences observed between the 
phenotypes it have been assessed several functional studies. 
Principal results are reported in Table 3 for KID analyzed 
mutations and in Table 4 for PPK and Vohwinkel analyzed 
mutations. Several studies in transfected cell systems, such 
as Xenopus oocytes or HeLa cells, have shown an aberrant 
hemichannel function for many mutations (Tables 3 and 4) 
[58, 59]. This aberrant hemichannel function may contribute 
to a loss of cell viability and tissue integrity, leading to rapid 
cell death, probably because of loss of ionic gradient and 
metabolites. By studying p.G12R and p.D50N mutations it 
has been determined a cellular death that could be rescued by 
introduction of Ca
2+ to the extracellular media during 
incubation. Moreover, it has been observed [20] by studying 
the effects of mutations p.G11E and p.D50N that alteration 
of calcium ion fluxes can result in cell death by necrosis 
[60]. Free cytoplasmic calcium content is increased in 
samples with mutated connexins, indicating that a major 
function of Cx26 is the regulation of calcium flux, whose 
deregulation leads to predominantly necrotic death.  482    Current Genomics, 2011, Vol. 12, No. 7  Iossa et al. 
  Recently, functional consequences of p.N14Y and 
p.N14K have been assessed, using fluorescently labelled 
proteins and parachute assay, and compared with that of the 
classical KID mutation p.D50N [61]. These analyses show 
that p.N14Y and p.N14K and p.D50N have different 
consequences for protein localization and gap junction 
permeability (Table 3). However, the differences between 
the phenotypes observed cannot be readily explained from 
effects on protein trafficking or gap junction permeability. 
  Besides aberrant hemichannel function, another putative 
mechanism of disease has also been proposed suggesting that 
the effect on functions can depends by the specific domain 
altered. Studies on a mutation associated with Vohwinkel 
syndrome (p.D66H) [62] and the GJB2 p.R75W missense 
mutation [63, 64], associated with sensorineural deafness 
and PPK, both located in EC1, have both a dominant 
negative effect on Cx26 gap junction assembly. It is thus 
suggested that alterations in the EC1 domain could impair 
proper docking of connexons. Moreover, mutations of some 
specific residues in the IC1 domains of connexins are 
consistently found in skin disorders (Table 2). The Glycine 
at position 11 or 12 of beta-group connexins seems to be of 
particular importance. The replacement of this glycine by a 
polar residue has been associated with skin disease in several 
connexins (Cx26 p.G12R in relation to KID, Cx31 p.G12R, 
p.G12D Cx30.3, p.G12D in EKV, and Cx30 p.G11R in 
Clouston syndrome) [59, 65-68]. Thus, it has been 
hypothesized that this conserved glycine maintains the 
flexibility of the NT and enables the gating of the channel by 
this domain. 
  By analyzing all identified mutations (Table 2), it could 
be observed that KID mutations essentially cluster in the first 
50 aminoacid (IC1-TM1-EC1 domains) (Table 2), with the 
exception of p.A88V (TM2 domain). Mutations in Cx26 
causing PPK–deafness syndrome mostly cluster in the EC1 
domain of Cx26 (with the exception of p.G130V located in 
the IC2 domain), but also mutation involved in other 
phenotypes BPS, Vohwinkel and Clouston syndromes are 
located in the same domains; so, further studies are necesary 
to determine if there is a clear correlation domain-involved 
and phenotype-associated.  
  Autosomal dominant mutations of the Cx26 gene may 
manifest effects on skin, perhaps due to their dominant-
negative effect on wild-type Cx26 and other connexins as 
determined by several studies [9, 45, 62, 63, 69, 70]. Recent 
studies have, in fact, shown that mutant forms of Cx26 
associated with skin disorders have an impact on the 
function of Cx43 and Cx30 [28, 45, 71, 72]. These results 
suggest that the precise phenotypes (deafness versus skin 
disease) resulting from the different dominant Cx26 mutants 
may depend upon both the nature of the physical interactions 
between different mutant and different wild-type connexins 
and upon their relative levels of expression in particular 
tissues. It is possible that the cell death associated with 
dominant connexin mutants results from causes other than 
direct disruption of tissue gap junction networks. Mutant 
connexins may exhibit entirely novel interactions with other 
key cellular proteins, reflected by their mislocation within 
the cell. This could lead to premature cell death 
independently of gap junction networks.  
  Mutations in connexin-associated protein could also 
explain the phenotypic variability observed among carriers 
of the same connexin mutation. It is likely that several 
syndromes here described are in fact multigenic disorders. 
Direct and in direct protein partners of connexins are still 
largely unknown. Further studies in this direction may 
explain the symptomatic variations of connexins diseases. 
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